Infectious Disease Treatment Market Set for Strong Growth Through 2030

Infectious diseases have shaped human history from the Black Death to COVID-19 and continue to be a significant global health challenge today. But the fight against these diseases is evolving rapidly. Thanks to modern medicine, innovative therapies, and international cooperation, we’re treating infections more effectively and anticipating and preparing for future outbreaks.

The global market for infectious disease treatments is expanding steadily. Driven by increased healthcare spending, emerging disease threats, and advances in biotechnology, the market is entering a new era marked by precision, prevention, and faster response.

According to market research, the global market for infectious disease treatments is expected to grow from $72.5 billion in 2025 to $101 billion by the end of 2030, at a compound annual growth rate (CAGR) of 6.9% from 2025 to 2030.

Why Infectious Disease Treatment Still Matters

Even with vaccines and preventive measures, infectious diseases remain a serious public health issue. The World Health Organization (WHO) states that infectious diseases account for over 25% of global deaths. Diseases like HIV/AIDS, hepatitis, tuberculosis, malaria, and influenza continue to affect millions of people annually, particularly in low- and middle-income countries.

The COVID-19 pandemic also revealed how fast an infectious disease can spread globally, overwhelming healthcare systems and triggering a race for treatments, diagnostics, and vaccines. As a result, governments, pharmaceutical companies, and health organizations are investing more in developing and stockpiling effective treatments.

Market Overview and Growth Outlook

The global market for infectious disease treatments includes antiviral, antibacterial, antifungal, and antiparasitic therapies. It encompasses prescription drugs, biologics, and emerging modalities like monoclonal antibodies, RNA-based therapies, and phage therapy.

The market’s growth is supported by:

• Increasing prevalence of infectious diseases
• Rising antibiotic resistance
• Greater awareness of pandemic preparedness
• Global investment in R&D and health infrastructure
• Adoption of personalized and targeted treatments

Regions like North America and Europe lead the market in innovation and regulatory frameworks. Meanwhile, Asia-Pacific, Latin America, and Africa are seeing rapid demand growth due to higher disease burden and expanding healthcare access.

Key Segments in Infectious Disease Treatment

The market is broadly segmented based on disease type, drug class, treatment approach, and geography.

1. By Disease Type

• Viral Infections: HIV/AIDS, hepatitis B and C, influenza, COVID-19, dengue, and RSV.
• Bacterial Infections: Tuberculosis, pneumonia, urinary tract infections, and drug-resistant bacteria.
• Fungal and Parasitic Infections: Candida, malaria, and leishmaniasis.

2. By Treatment Type

• Antibiotics: Still a backbone for bacterial infections, but facing challenges from antibiotic resistance.
• Antivirals: Rapidly expanding with new drugs for hepatitis, herpes, influenza, and SARS-CoV-2.
• Biologics and Immunotherapies: Monoclonal antibodies and immunomodulators for serious or drug-resistant infections.
• Combination Therapies: Used to increase effectiveness and reduce resistance.